Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

The 2020 ACR Review Course: Key Issues Rheumatologists Face

Jason Liebowitz, MD, FACR  |  Issue: January 2021  |  December 17, 2020

Dr. Clowse also referred to the ACR guideline in discussing appropriate contraceptive options for patients, medications that are safe for pregnant or lactating mothers, and even how to counsel patients on the use of assistive reproductive technologies.

Pediatric Rheumatology
Eveline Wu, MD, MSCR, associate professor of pediatric rheumatology at University of North Carolina Children’s Research Institute, Chapel Hill, provided a pediatric rheumatology review geared toward the adult rheumatologist. Dr. Wu began her talk by noting how important it is for adult and pediatric rheumatologists to collaborate, especially given the scarcity of physicians practicing pediatric rheumatology—in fact, about 10 states have no pediatric rheumatologists at present.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Wu next addressed the topic of juvenile arthritis-associated temporomandibular joint (TMJ) disease. Among the subtypes of juvenile idiopathic arthritis (JIA), patients who are rheumatoid factor negative and with polyarticular disease are at particularly high risk of TMJ involvement, although all categories of JIA are at risk and about 40–80% of patients with JIA will have TMJ arthritis. This is important because TMJ disease can cause abnormal dentofacial development and significant facial disabilities, including orofacial pain, reduced TMJ mobility and impaired mastication function.

The clinical evaluation should include palpating the joint to try to elicit tenderness, noting clicking or crepitus with joint movement and identifying asymmetry of the face at rest and deviation with mouth opening. Magnetic resonance imaging with contrast is the gold standard of imaging, and intra-articular corticosteroid injections and intra-articular lavage without corticosteroid are effective treatments.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The second main clinical topic Dr. Wu discussed was JIA-associated uveitis, which is the most common extra-articular complication of the disease. In the SYCAMORE study, patients with JIA-associated uveitis who were age 2 years or older and on a stable dose of methotrexate were randomized to receive either adalimumab or placebo. After two years of follow-up, patients receiving adalimumab therapy had lower rates of treatment failure (27% vs. 60%, respectively), indicating the efficacy of this treatment.

Dr. Wu concluded her talk with a discussion of multi-system inflammatory syndrome in children (MIS-C), a rare but serious condition that shares many features of Kawasaki disease and has emerged with the COVID-19 pandemic. The ACR clinical guidance document on MIS-C describes this disease as a condition characterized by fever, inflammation and multi-organ dysfunction that manifests late in the course of SARS-CoV-2 infection.13 Dr. Wu explained that much remains to be understood about MIS-C and that this disease will be one of the most important issues related to COVID-19 in the world of pediatric rheumatology.

Page: 1 2 3 4 5 6 7 | Single Page
Share: 

Filed under:ACR ConvergenceConditionsMeeting ReportsOsteoarthritis and Bone DisordersPediatric ConditionsVasculitis Tagged with:ACR Convergence 2020liver diseasemeeting reportsOsteoporosisPediatricpregnancyVasculitis

Related Articles

    TNF Blockade for SLE

    September 1, 2010

    Reckless approach versus missed opportunity?

    Tacrolimus Use for Lupus Nephritis Raises Debate over Role in North American Population

    October 10, 2016

    The following summary regarding use of tacrolimus (TAC) in lupus nephritis highlights a number of debatable points. Although the role of TAC in lupus nephritis remains unproved for North American populations, it might be an excellent option in some clinical situations. These situations include lupus flare during pregnancy and also for lupus nephritis when the…

    State-of-the-Art Approaches to Rheumatic Disease Diagnosis, Management & Treatment

    March 19, 2019

    CHICAGO—Held during the 2018 ACR/ARHP Annual Meeting, the ACR Review Course covered a wide range of topics for rheumatologists—from advances in pain and rheumatic disease management to the intersection of rheumatology and neurology. Session speakers shared insights, as well as state-of-the-art approaches to diagnosis, management and treatment. Inflammatory Myopathies Julie J. Paik, MD, MHS, assistant…

    Lupus Nephritis: Understanding the Paradigm for Treatment

    June 16, 2020

    ACR BEYOND LIVE—Among patients with systemic lupus erythematosus (SLE), lupus nephritis remains one of the leading causes of mortality, and patients with both SLE and end-stage renal disease demonstrate standardized mortality ratios higher than 60 times that of patients with SLE who have normal kidney function.1 Although the ACR Guidelines for Screening, Treatment, and Management…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences